Monopar Therapeutics reported a net loss of $3.4 million for the third quarter of 2025, with total operating expenses of $4.092 million—$2.589 million in research and development and $1.503 million in general and administrative costs. Cash, cash equivalents and investments rose to $143.7 million at the end of September, a jump from $54.6 million reported in March. The loss reflects higher R&D and G&A spending driven by manufacturing activities for its Wilson disease candidate and increased personnel costs, but the expanded cash balance extends the company’s runway well beyond the end of 2027.
The company completed a $126.9 million public offering, of which $35 million was allocated to repurchase 550,229 shares from Tactic Pharma LLC. Net proceeds of approximately $91.9 million were added to cash, reinforcing liquidity and reducing dilution for remaining shareholders. The share buyback also consolidates ownership after a major shareholder divestiture, positioning the company for future capital needs.
Monopar’s management reiterated its focus on the ALXN1840 program, expecting to file a New Drug Application in early 2026, and on the MNPR‑101 radiopharmaceutical trials. The current cash runway is projected to cover these milestones, with additional funding earmarked for later‑stage development and potential commercialization. The guidance underscores a strategy of advancing key pipeline assets while maintaining financial flexibility.
Earnings per share for the quarter were $‑0.48, missing the consensus estimate of $‑0.35. The miss is largely attributable to the higher R&D and G&A expenses noted above; it is smaller than the prior‑quarter miss (EPS $‑0.35 vs estimate $‑0.48), indicating a narrowing gap between performance and expectations.
Analyst coverage has been positive, with Leerink Partners upgrading Monopar in anticipation of the earnings release. The upgrade reflects confidence in the company’s robust cash position, clear pipeline milestones, and the strategic value of its share repurchase program.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.